



## US LEGAL PROCEEDING

---

**11 April 2025, Adelaide Australia:** Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma) has been served with a legal proceeding filed against one of its US subsidiaries, Mayne Pharma LLC, in the United States District Court for the District of Delaware.

The proceeding is brought by TherapeuticsMD, Inc. (TXMD) as the plaintiff. The proceeding alleges breach of contract, breach of implied covenant of good faith and fair dealing, fraudulent inducement to settle a prior portion of the net working capital adjustment and unjust enrichment related to Mayne Pharma LLC's calculation of amounts owed by TXMD for various net working capital adjustments under the Transaction Agreement entered into between TXMD and Mayne Pharma LLC on 4 December 2022 (Transaction Agreement).

These claims are related to one of a series of disputes that have been in discussion between Mayne Pharma and TXMD for some time. Mayne Pharma intends to vigorously defend the proceeding. Additionally, Mayne Pharma has a number of separate claims against TXMD that allege damages which Mayne Pharma believes are in excess of the value of the claims made by TXMD in this proceeding and will address those in due course. This proceeding is not an attempt to terminate the Transaction Agreement, the License Agreement entered into between TXMD and Mayne Pharma LLC on 4 December 2022, or Mayne Pharma's rights with respect to the products licensed from TXMD.

Mayne Pharma emphatically denies any and all allegations of wrongdoing and believes the proceeding to be without merit, but there is no assurance that Mayne Pharma would be successful in any defence thereof.

**For further information contact:**

Dr Tom Duthy

+61 402 493 727

[ir@maynepharma.com](mailto:ir@maynepharma.com)

Authorised for release to the ASX by the Chair

**About Mayne Pharma**

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](https://maynepharma.com).